Drug Trial Radar · NCT06325930
A Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-HU6
Last checked: Nov 19, 2026Latest source record: May 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8
Actual
Start
Mar 26, 2024
Primary completion
May 7, 2024
Study completion May 7, 2024
Sponsor
- Lead sponsor
- Rivus Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 22, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single-center, non-randomized, open-label Phase 1 study to characterize the absorption, metabolism, excretion, mass balance, pharmacokinetics (PK), safety and tolerability of HU6 following administration of a single dose of \[14C\]-HU6 in a fed state with a standard meal administered approximately 15 minutes prior to dosing.
Conditions
- Healthy
Interventions
[14C]-HU6Drug
\[14C\]-HU6 following a single dose of HU6 in healthy, adult male subjects
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess the mass balanceTime frame: Up to Day 29
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Pharmaron Clinical Pharmacology Center (CPC)
Baltimore, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.